JP Morgan maintains Becton Dickinson at Neutral, raises price target to $202 from $170
JP Morgan kept Becton Dickinson at Neutral but raised its price target to $202 from $170, suggesting a 4.7% downside from the Nov 6 close of $211.88. Recent analyst targets range from $200 to $242.
How this was made

The 30-second read
Why it matters
The upgrade may affect short-term trading as the stock trades above the new target, possibly prompting profit-taking.
Market read
Analyst price target changes can move investor sentiment and short-term price action for the stock.
What to watch
Potential supply chain constraints or regulatory risks not addressed in the note.
Background
JP Morgan's analyst note updates the price target for Becton Dickinson, reflecting a revised outlook.
Ticker impact
JP Morgan raised its price target on Becton Dickinson to $202 from $170.
potential downside as the market may price in the higher target while the stock trades above it
The target increase signals confidence, yet the current price exceeds the new target, likely prompting short-term pressure.
Market effects
May influence sentiment in the medical devices sector as analysts adjust expectations.
Limited to US markets where BDX is listed.
Low global impact beyond sector peers.
Counterpoint
The price target raise could be premature if recent earnings missed expectations.
Key entities
- companyBecton Dickinson
Medical device manufacturer (ticker BDX).
- analystJP Morgan
Investment bank providing the price target revision.



